

# Gulen Hatemi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3330298/gulen-hatemi-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123  
papers

3,608  
citations

29  
h-index

57  
g-index

148  
ext. papers

4,660  
ext. citations

4.9  
avg, IF

5.41  
L-index

#	Paper	IF	Citations
123	EULAR recommendations for the management of Behçet disease. <i>Annals of the Rheumatic Diseases</i> , <b>2008</b> , 67, 1656-62	2.4	478
122	2018 update of the EULAR recommendations for the management of Behçet's syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 808-818	2.4	277
121	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 19-30	2.4	270
120	Behçet syndrome: a contemporary view. <i>Nature Reviews Rheumatology</i> , <b>2018</b> , 14, 107-119	8.1	167
119	Apremilast for Behçet's syndrome—a phase 2, placebo-controlled study. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1510-8	59.2	157
118	Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 1528-34	2.4	131
117	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1744-50	2.4	114
116	Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. <i>Medicine (United States)</i> , <b>2012</b> , 91, 35-48	1.8	112
115	Canakinumab in a patient with juvenile Behçet's syndrome with refractory eye disease. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1589-91	2.4	80
114	Increased enthesopathy among Behçet's syndrome patients with acne and arthritis: an ultrasonography study. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1539-45		78
113	Behçet's syndrome. <i>Rheumatic Disease Clinics of North America</i> , <b>2013</b> , 39, 245-61	2.4	75
112	Trial of Apremilast for Oral Ulcers in Behçet's Syndrome. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1918-1928	59.2	65
111	Atherosclerosis in Behçet's Syndrome. <i>Seminars in Arthritis and Rheumatism</i> , <b>2008</b> , 38, 1-12	5.3	63
110	Behçet's syndrome: a critical digest of the 2014-2015 literature. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S3-14	2.2	62
109	Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor- $\alpha$ Inhibitors: Report From a Large Multicenter Cohort with High Background Prevalence. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 524-9	4.1	58
108	Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. <i>Rheumatology</i> , <b>2018</b> , 57, 2200-2212	3.9	57
107	Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behçet's Syndrome: A Strobe-Compliant Observational Study From a Dedicated Multidisciplinary Center. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3348	1.8	52

106	Pulmonary artery involvement in Behçet's syndrome: Effects of anti-Tnf treatment. <i>Seminars in Arthritis and Rheumatism</i> , <b>2015</b> , 45, 369-73	5.3	46
105	Behçet's Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1085	8.4	43
104	Outcome measures used in clinical trials for Behçet syndrome: a systematic review. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 599-612	4.1	41
103	Behçet's syndrome: a critical digest of the 2013-2014 literature. <i>Clinical and Experimental Rheumatology</i> , <b>2014</b> , 32, S112-22	2.2	39
102	Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 752-762	5.3	38
101	Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases. <i>Rheumatology</i> , <b>2013</b> , 52, 1923-4	3.9	38
100	Ocular Involvement of Behçet's Syndrome: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2015</b> , 49, 298-306	12.3	36
99	Behçet syndrome manifestations and activity in the United States versus Turkey -- a cross-sectional cohort comparison. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1379-84	4.1	34
98	Tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , <b>2008</b> , 27, 1243-8	3.9	33
97	Gastrointestinal Involvement in Behçet Disease. <i>Rheumatic Disease Clinics of North America</i> , <b>2018</b> , 44, 45-64	2.4	32
96	Bone marrow transplantation for Behçet's disease: a case report and systematic review of the literature. <i>Rheumatology</i> , <b>2014</b> , 53, 1136-41	3.9	29
95	Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial. <i>Rheumatology</i> , <b>2010</b> , 49, 173-7	3.9	28
94	Bilateral inflammatory breast metastases of epithelial ovarian cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1999</b> , 22, 408-10	2.7	28
93	Behçet's syndrome and micro-organisms. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2011</b> , 25, 389-406	5.3	27
92	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2465-9	4.1	26
91	The papulopustular lesion/arthritis cluster of Behçet's syndrome also clusters in families. <i>Rheumatology</i> , <b>2012</b> , 51, 1053-60	3.9	26
90	Current status of outcome measure development in vasculitis. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 593-84.1		25
89	Analysis of MEFV exon methylation and expression patterns in familial Mediterranean fever. <i>BMC Medical Genetics</i> , <b>2011</b> , 12, 105	2.1	25

88	Update on the treatment of Behçet's syndrome. <i>Internal and Emergency Medicine</i> , <b>2019</b> , 14, 661-675	3.7	24
87	Novel NLRP3/cryopyrin mutations and pro-inflammatory cytokine profiles in Behçet's syndrome patients. <i>International Immunology</i> , <b>2014</b> , 26, 71-81	4.9	23
86	TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S129-37	2.2	23
85	Behçet's syndrome: providing integrated care. <i>Journal of Multidisciplinary Healthcare</i> , <b>2017</b> , 10, 309-319	2.8	22
84	Treating the Different Phenotypes of Behçet's Syndrome. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2830	8.4	22
83	Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, R147	5.7	21
82	Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. <i>Annals of Hematology</i> , <b>2005</b> , 84, 609-13	3	21
81	Increased serum sialic acid levels in primary osteoarthritis and inactive rheumatoid arthritis. <i>Tohoku Journal of Experimental Medicine</i> , <b>2007</b> , 213, 241-8	2.4	19
80	Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1750-1753	4.1	18
79	Management of Behçet's syndrome. <i>Current Opinion in Rheumatology</i> , <b>2016</b> , 28, 45-50	5.3	18
78	A reappraisal of the association between Behçet's disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S145-51	2.2	18
77	Analyses of functional IL10 and TNF- $\alpha$ genotypes in Behçet's syndrome. <i>Molecular Biology Reports</i> , <b>2010</b> , 37, 3637-41	2.8	17
76	Infliximab does not suppress the tuberculin skin test (purified protein derivative). <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 474-80	4.1	17
75	No appreciable decrease in fertility in Behçet's syndrome. <i>Rheumatology</i> , <b>2014</b> , 53, 828-33	3.9	16
74	Necrotizing vasculitis associated with familial Mediterranean fever. <i>American Journal of Medicine</i> , <b>2004</b> , 117, 516-9	2.4	16
73	Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy. <i>Rheumatology International</i> , <b>2016</b> , 36, 1719-1725	3.6	15
72	Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2436-41	4.1	14
71	Systemic vasculitis and the gut. <i>Current Opinion in Rheumatology</i> , <b>2017</b> , 29, 33-38	5.3	13

70	Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome. <i>Rheumatology</i> , <b>2020</b> , 59, 799-806	3.9	13
69	Biomarkers in vasculitis. <i>Current Opinion in Rheumatology</i> , <b>2018</b> , 30, 30-35	5.3	12
68	Colchicine in Behçet syndrome: a longterm survey of patients in a controlled trial. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 735-8	4.1	12
67	One year in review 2016: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 10-22	2.2	12
66	Reply to letter by Priori et al commenting on whether Behçet's syndrome patients with acne and arthritis comprise a true subset. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 305-6		11
65	Long term follow-up of Behçet's syndrome patients treated with cyclophosphamide. <i>Rheumatology</i> , <b>2020</b> , 59, 2264-2271	3.9	11
64	Management of Behçet's syndrome. <i>Current Opinion in Rheumatology</i> , <b>2014</b> , 26, 285-91	5.3	10
63	Genetic susceptibility to Behçet's syndrome is associated with NRAMP1 (SLC11A1) polymorphism in Turkish patients. <i>Rheumatology International</i> , <b>2009</b> , 29, 787-91	3.6	9
62	Global epidemiology of vasculitis. <i>Nature Reviews Rheumatology</i> , <b>2021</b> ,	8.1	9
61	Management of large-vessel vasculitis. <i>Current Opinion in Rheumatology</i> , <b>2019</b> , 31, 25-31	5.3	9
60	One year in review 2017: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 108, 3-15	2.2	9
59	One year in review 2019: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 121, 3-17	2.2	9
58	Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study. <i>Medicine (United States)</i> , <b>2017</b> , 96, e7859	1.8	8
57	Fatigue is correlated with disease activity but not with the type of organ involvement in Behçet's syndrome: a comparative clinical survey. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S107-12	2.2	8
56	Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 108, 86-89	2.2	8
55	One year in review 2018: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 13-27	2.2	8
54	How to treat myelodysplastic syndrome with clinical features resembling Behçet syndrome: a case-based systematic review. <i>Annals of Hematology</i> , <b>2020</b> , 99, 1193-1203	3	7
53	Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Behçet's Syndrome. <i>The Cochrane Library</i> , <b>2014</b> , CD010729	5.2	7

52	Who are the young professionals working in the field of rheumatology in Europe and what are their needs? An EMEUNET (EMerging EUlar NETwork) survey. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1432-34	2.4	7
51	The OMERACT Core Set of Domains for Outcome Measures in Behçet Syndrome. <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	7
50	Behçet's syndrome: a critical digest of the 2012-2013 literature. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 108-17	2.2	7
49	Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet's syndrome patients with gastrointestinal involvement. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 90-96	2.2	7
48	Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies. <i>Rheumatology International</i> , <b>2018</b> , 38, 607-622	3.6	6
47	Sexual dysfunction and depression in premenopausal women with mucocutaneous Behçet's disease. <i>International Journal of Rheumatic Diseases</i> , <b>2013</b> , 16, 463-8	2.3	6
46	COVID-19 Among Patients With Inflammatory Rheumatic Diseases. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 651715	8.4	6
45	Behçet syndrome. <i>Nature Reviews Disease Primers</i> , <b>2021</b> , 7, 67	51.1	6
44	Double pylorus in a patient with Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S138-40	2.2	6
43	One year in review 2020: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 127, 3-10	2.2	6
42	Currently Used Biologic Agents in the Management of Behçet's Syndrome. <i>Current Medicinal Chemistry</i> , <b>2015</b> , 22, 1976-85	4.3	5
41	Suicidal ideation among patients with Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S30-5	2.2	5
40	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1198-1201	4.1	4
39	Turkish PASE: Turkish Version of the Psoriatic Arthritis Screening and Evaluation Questionnaire. <i>Annals of Dermatology</i> , <b>2014</b> , 26, 457-61	0.4	4
38	The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome. <i>Rheumatology International</i> , <b>2021</b> , 1	3.6	4
37	Behçet's disease: an MHC-I-opathy?. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 104, 5	2.2	4
36	One year in review 2021: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 3-13	2.2	4
35	Development of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) and brain tumor in a patient after more than 7 years of omalizumab use: A case report. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2015</b> , 28, 134-7	3	3

34	Patients' experiences with Behçet's syndrome: structured interviews among patients with different types of organ involvement. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 121, 28-34	2.2	3
33	Biosimilar infliximab for Behçet's syndrome: a case series. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 121, 111-115	2.2	3
32	Apremilast for the treatment of Behçet syndrome. <i>Expert Opinion on Orphan Drugs</i> , <b>2017</b> , 5, 677-681	1.1	2
31	JAK2 (V617F) mutation is not associated with thrombosis in Behçet syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2012</b> , 18, 421-6	3.3	2
30	Should maintenance therapy be performed in ulcerative proctitis? How long should it be continued?. <i>Turkish Journal of Gastroenterology</i> , <b>2012</b> , 23 Suppl 2, 21-4	1	2
29	Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 618973	8.4	2
28	Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates. <i>Rheumatology International</i> , <b>2021</b> , 1	3.6	2
27	Recommendations in the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Related to the Use of Biologic Agents in Patients With a History of Cancer Need Reconsideration: Comment on the Article by Singh et al. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1315-6	9.5	2
26	THU0303 THE OMERACT CORE DOMAIN SET FOR CLINICAL TRIALS IN BEHÇET'S SYNDROME <b>2019</b> ,		2
25	Assessing the possible association of anti-TNF use with new malignancies: A neglected methodological consideration. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 894-901	2.6	1
24	Takayasu arteritis. <i>Current Opinion in Rheumatology</i> , <b>2022</b> , 34, 18-24	5.3	1
23	Disease Assessment in Behçet Syndrome <b>2020</b> , 261-278		1
22	A treat-to-target approach is needed for Behçet's syndrome. <i>Current Opinion in Rheumatology</i> , <b>2022</b> , 34, 39-45	5.3	1
21	Behçet Syndrome and Microbes <b>2020</b> , 191-199		1
20	Recent Insights into the Management of Behçet Syndrome. <i>Journal of Inflammation Research</i> , <b>2021</b> , 14, 3429-3441	4.8	1
19	Recommendations in the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Related to the Use of Biologic Agents in Patients With a History of Cancer Need Reconsideration: Comment on the Article by Singh et al. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 724	4.7	1
18	Diagnostic Criteria as Separate From Classification Criteria: A Perpetual Motion Machine? Comment on the Article by Aggarwal et al. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 1049	4.7	1
17	Aortic involvement in relapsing polychondritis: case-based review. <i>Rheumatology International</i> , <b>2021</b> , 41, 827-837	3.6	1

16	An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet's syndrome. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 1533-1537	4	1
15	Locomotor System Disease in Behçet Syndrome <b>2010</b> , 149-163		1
14	Tapering tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective study. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 122, 8	2.2	1
13	Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 80-87	2.2	1
12	Disease course and healthcare costs of a cohort of rheumatoid arthritis patients from Turkey. <i>Rheumatology International</i> , <b>2020</b> , 40, 1037-1044	3.6	0
11	Comment on: Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome: reply. <i>Rheumatology</i> , <b>2020</b> , 59, 914-915	3.9	
10	Inadequate reporting of enrolled patient and study site characteristics, and inter-study site differences in randomized controlled trials: A systematic review in six leading medicine journals. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 37, e34-e36	3.9	
9	F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging Appearance of Gastrointestinal Behçet's Disease.. <i>Molecular Imaging and Radionuclide Therapy</i> , <b>2022</b> , 31, 57-59	0.8	
8	Method. <i>Turkish Journal of Gastroenterology</i> , <b>2017</b> , 28, S3		1
7	A Few Suggestions for Further Research <b>2020</b> , 315-319		
6	Do anti-TNF agents and combination treatment increase postoperative complication risk?. <i>Turkish Journal of Gastroenterology</i> , <b>2012</b> , 23 Suppl 2, 25-9		1
5	Acknowledged statistical help and a better use of p values: a proposal. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 855-857	2.2	
4	Bone marrow oedema on sacroiliac/spine MRI: is it really a sign of objective inflammation warranting treatment?. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 122, 10	2.2	
3	The improper use of a no-treatment group in the randomised surgical trial for subacromial shoulder pain. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 122, 9	2.2	
2	One year in review 2021: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 132, 3-13	2.2	
1	Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 132, 80-87	2.2	